The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Responses to avapritinib in patients with advanced systemic mastocytosis
Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT, discusses the efficacy of avapritinib in patients with advanced systemic mastocytosis. In this video, Dr George highlights the decrease in mast cell burden and hypercellularity in the bone marrow and the promise of this agent for the treatment of systemic mastocytosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultant, cogent blueprint
